Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05279027 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Zr89 + PET Companion Trial

StatusActive, Not Recruiting
PhaseEarly Phase 1
Started
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary completion moved at least 7 months later Dec 18, 2025 → Jul 30, 2026
See other at-risk trials from Abramson Cancer Center at Penn Medicine

Record History

  1. Primary completion pushed from Dec 18, 2025 to Jul 30, 2026 Completion moved earlier from Dec 18, 2027 to May 12, 2027 · Primary completion date changed from estimate of Jul 31, 2026 to Dec 18, 2025 · Completion pushed from May 12, 2027 to Dec 18, 2027 Show 3 more changesShow less
    • Completion moved earlier from Dec 18, 2027 to May 12, 2027
    • Primary completion date changed from estimate of Jul 31, 2026 to Dec 18, 2025
    • Completion pushed from May 12, 2027 to Dec 18, 2027
  2. Primary completion date changed from estimate of Jul 31, 2026 to Dec 18, 2025 Completion date: May 12, 2027 to Dec 18, 2027 · Eligibility criteria expanded, about 2 words Show 2 more changesShow less
    • Completion date: May 12, 2027 to Dec 18, 2027
    • Eligibility criteria expanded, about 2 words
  3. Primary completion date: May 6, 2025 to Jul 31, 2026 Trial status: Completed to Active, Not Recruiting · Completion date: May 6, 2025 to May 12, 2027v9 Show 2 more changesShow less
    • Trial status: Completed to Active, Not Recruiting
    • Completion date: May 6, 2025 to May 12, 2027
  4. Trial status: Enrolling by Invitation to Completed Enrollment target: estimated 20 to confirmed 6 · Primary completion date changed from estimate of Dec 31, 2028 to May 6, 2025 · Study completion date changed from estimate of Dec 31, 2029 to May 6, 2025v8 Show 3 more changesShow less
    • Enrollment target: estimated 20 to confirmed 6
    • Primary completion date changed from estimate of Dec 31, 2028 to May 6, 2025
    • Study completion date changed from estimate of Dec 31, 2029 to May 6, 2025
  5. Primary completion date: Dec 31, 2024 to Dec 31, 2028 Completion date: Feb 28, 2025 to Dec 31, 2029v7 Show 1 more changeShow less
    • Completion date: Feb 28, 2025 to Dec 31, 2029
Show 5 earlier versionsHide 5 earlier versions
  1. Re-verified, no change to tracked fieldsv6
  2. Primary completion date: Dec 2025 to Dec 31, 2024 Completion date: Dec 2025 to Feb 28, 2025v5 Show 1 more changeShow less
    • Completion date: Dec 2025 to Feb 28, 2025
  3. Study description revisedv4 See this version in full on ClinicalTrials.gov ↗
  4. Primary completion date: Dec 31, 2024 to Dec 2025 Primary endpoints revised (2) · Completion date: Feb 28, 2025 to Dec 2025 · Interventions: 89Zr-Df-IAB22M2C PET/CT (Drug) to Zirconium Zr 89 Crefmirlimab Berdoxa (Drug) · 3 morev3 Show 6 more changesShow less
    • Primary endpoints revised (2)
    • Completion date: Feb 28, 2025 to Dec 2025
    • Interventions: 89Zr-Df-IAB22M2C PET/CT (Drug) to Zirconium Zr 89 Crefmirlimab Berdoxa (Drug)
    • Secondary endpoints: details revised at 2 of 2 entries
    • Study description expanded, about 31 words
    • Study title expanded, about 1 word

    See this version in full on ClinicalTrials.gov ↗

  5. Re-verified, no change to tracked fieldsv2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Study of Zirconium Zr 89 Crefmirlimab Berdoxa PET/CT as an imaging biomarker for assessing an early response to therapy in patients with advanced melanoma on immunotherapy and hydroxychloroquine. This study is a companion study to the "LIMIT Melanoma Trial." Patients with melanoma who are potentially eligible for the LIMIT Melanoma Trial and have at least one site of measurable disease based on RECIST 1.1 are potentially eligible. Associations with progression-free survival (PFS) and overall survival (OS) will be tested.
Trial Details
NCT Number NCT05279027
Lead Sponsor Abramson Cancer Center at Penn Medicine
Collaborators: ImaginAb, Inc.
Conditions Melanoma (Skin)
Enrollment 6 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov